Related Experiment Video
Updated: Aug 16, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
CD28 superagonists: mode of action and therapeutic potential
1Institute for Virology and Immunology, University of Würzburg, Versbacher Strasse 7, 97078 Würzburg, Germany. huenig@vim.uni-wuerzburg.de
Abstract:
Some CD28-specific monoclonal antibodies (mAbs) have the surprising property to activate T-cells without the need for TCR ligation. This review summarizes the differences between these "superagonistic" and conventional CD28-specific mAbs with regard to binding specificity and signalling properties. Furthermore, the dramatic effects of in vivo application of CD28 superagonists with regard to the induction of regulatory T-cells and polyclonal T-cell expansion in lymphopenic settings are discussed under the aspect of potential therapeutic applications.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Mitogens and the Cell Cycle
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

